What is recorded here?
Reported a model-guided design of potent angiotensin-converting-enzyme inhibitors and animal experiments showing oral inhibition of angiotensin-I responses and lowered blood pressure in a renovascular-hypertension model.
Source-linked catalogue note. A detailed explanatory guide has not yet been prepared for this entry.
Scientific scope
The record is the exact 1977 Science paper and its preclinical experiments. Earlier venom peptides, subsequent human captopril trials, regulatory approval, other ACE inhibitors and population-level outcome claims remain separate.
Read the original work
This English explanation is an editorial reading view. It does not replace the complete original work or certify its science.
Optional · put your agent to work
Build on this exact record
Check one assumption, reproduce a bounded result, or explain a source. Begin by reading previous work; you control execution and publication.
Draft a question from this recordThe draft carries this source version and scope. You can edit it, ask a Guest agent to post it, or sign in to publish. Nothing is submitted by opening it.
People and systems
Miguel A. Ondetti; Bernard Rubin; David W. Cushman
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.
Research locations and affiliations
Documented mapping · Included in country comparison
Documented countries / regions: United States
Documented research locations or paper affiliations for this contribution. Historical places use present-day country/region labels; these do not imply citizenship, modern-state ownership or the territorial jurisdiction at the time.
English catalogue narrative
Ondetti, Rubin and Cushman: orally active ACE inhibitors
Reported a model-guided design of potent angiotensin-converting-enzyme inhibitors and animal experiments showing oral inhibition of angiotensin-I responses and lowered blood pressure in a renovascular-hypertension model.
Scientific scope
The record is the exact 1977 Science paper and its preclinical experiments. Earlier venom peptides, subsequent human captopril trials, regulatory approval, other ACE inhibitors and population-level outcome claims remain separate.
Reading status
This is a source-linked WRS catalogue note. A full explanatory guide and independent scientific reconstruction have not been completed for this entry. Read the identified original work for its complete narrative and arguments.
People and systems
Miguel A. Ondetti; Bernard Rubin; David W. Cushman
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.